Still, in terms of timing of administration, it is debatable if targeted therapy should be administered before, at the same time or after ICIs; although, the changes induced in the microenvironment by BRAF inhibitors including reducing immunosuppressive cytokines, increasing availability of tumor antigens and infiltration of tumors by immune cells may sensitize tumors to ICIs (Dummer et al., 2020). Here, BRAF is linked to neoplasm.